Natco Pharma is an API and finished-dose manufacturer based in India. It holds 102 active US drug master files and 12 valid CEPs. Its filings concentrate with Health Canada, US FDA and CDSCO (India). Its GMP standing is certified by ANVISA (Brazil), EMA and US FDA, among 7 authorities. Its most recent recorded inspection, by US FDA, closed on 21 November 2025 as VAI. Customs aggregates show $87.4M of exports covering 1,402 molecules to 55 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Anakapalli, India | 3015380536 |
| Chennai, India | 3009870595 |
| Rangareddy, India | 3004065860 |
| Rangareddy, India | 3004540906 |
| RANGAREDDY, India | Not on file |
| Kothur, India | Not on file |
4 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Letrozole | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Ondansetron | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Rizatriptan | EDQM, US FDA | 5 |
| Sumatriptan | EDQM, US FDA | 5 |
| Anastrozole | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Apixaban | SFDA (Saudi Arabia), US FDA | 4 |
| Granisetron | US FDA | 4 |
| Ibandronate | US FDA | 4 |
| Zoledronic Acid | SFDA (Saudi Arabia), US FDA | 4 |
| Acalabrutinib | SFDA (Saudi Arabia), US FDA | 3 |
| Bendamustine | SFDA (Saudi Arabia), US FDA | 3 |
| Capmatinib | SFDA (Saudi Arabia), US FDA | 3 |
| Cidofovir | SFDA (Saudi Arabia), US FDA | 3 |
| Citalopram | EDQM, US FDA | 3 |
| Eribulin | SFDA (Saudi Arabia), US FDA | 3 |
| Everolimus | SFDA (Saudi Arabia), US FDA | 3 |
| Gefitinib | EDQM, US FDA | 3 |
| Ibrutinib | SFDA (Saudi Arabia), US FDA | 3 |
| Imatinib | SFDA (Saudi Arabia), US FDA | 3 |
| Omeprazole | EDQM, US FDA | 3 |
| Pomalidomide | SFDA (Saudi Arabia), US FDA | 3 |
| Salmeterol | EDQM, US FDA | 3 |
| Sorafenib | SFDA (Saudi Arabia), US FDA | 3 |
| Sugammadex | SFDA (Saudi Arabia), US FDA | 3 |
| Teriflunomide | SFDA (Saudi Arabia), US FDA | 3 |
| Tipiracil | SFDA (Saudi Arabia), US FDA | 3 |
| Trifluridine | SFDA (Saudi Arabia), US FDA | 3 |
| Alectinib | US FDA | 2 |
| Bortezomib | US FDA | 2 |
| Cabozantinib | US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| Health Canada | 211 | None |
| US FDA | 157 | 3 |
| CDSCO (India) | 24 | 2 |
| HSA (SG) | 16 | 2 |
| JFDA (JO) | 13 | None |
| NCELS (KZ) | 11 | None |
| ANVISA (Brazil) | None | 10 |
| EMA | None | 5 |
| FDA (GH) | None | 1 |
| NAFDAC (NG) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $15.8M | 27 |
| 2025 | $517.5M | $87.4M | 55 |
| 2024 | $479.5M | $62.1M | 54 |
| 2023 | $329.3M | $73.4M | 57 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Natco Pharma comes back tiered against every other supplier able to file there.
Start for free